Microsatellite instability (MSI) has been detected in endometrial carcinomas occurring in women aected by hereditary nonpolyposis colorectal carcinoma (HNPCC) as well as in 20% of presumably sporadic endometrial tumors. While the MSI+ phenotype observed in endometrial tumors from HNPCC patients is attributed to germ line mutations in mismatch repair (MMR) genes, somatic mutations of known MMR genes are infrequent in MSI+ sporadic endometrial carcinomas. Recently, cytosine methylation of the MLH1 promoter region has been identi®ed in a subset of MSI+ colon primary carcinomas and cell lines. We studied the MLH1 and MSH2 promoter methylation status in 29 presumably sporadic uterine endometrioid carcinomas (UECs), which had previously been characterized for the MSI phenotype and a subset for DNA MMR gene mutational status. We found that 13 (45%) of 29 cases of EC were hypermethylated in the 5' CpG island of MLH1. Hypermethylation of MSH2 was not observed. MLH1 was hypermethylated in 12 (92%) of 13 MSI+ tumors, while only 1 (6%) of 16 MSI-tumors (Fischer's exact test P50.0001). Other tumor types we tested did not demonstrate MLH1 promoter hypermethylation. Our data suggest that hypermethylation of MLH1, but not of MSH2, is associated with the MSI phenotype in sporadic endometrial carcinomas.
Introduction
Endometrial carcinoma is the most common noncolorectal carcinoma occurring in women with familial cancer syndrome HNPCC . Colon and endometrial carcinomas in HNPCC patients display microsatellite instability (MSI). In this setting, the cause of MSI has been attributed to defects in DNA mismatch repair Thibodeau et al., 1993; Ionov et al., 1993) . Several dierent MMR genes, including hMHS2, MLH1, hPMS2, hMSH3 and hMSH6 have been identi®ed (Fishel et al., 1993; Leach et al., 1993; Bronner et al., 1994; Nicolaides et al., 1994 Nicolaides et al., , 1995 . Recently, it has been estimated that germ line mutations of MSH2 and MLH1 are found in the majority of HNPCC kindreds Kolodner et al., 1995) .
MSI has also been observed in a subset of sporadic colorectal cancers, and in approximately 20% of sporadic endometrial carcinomas (Risinger et al., 1993; Burks et al., 1994; Duggan et al., 1994; Kobayashi et al., 1995 Kobayashi et al., , 1996 Cadu et al., 1996; Katabuchi et al., 1995; Lim et al., 1996; Kowalski et al., 1997) . The MSI phenotype appears to be restricted to uterine endometrioid carcinomas (UECs), the most common type of endometrial carcinoma. It might be expected that UECs with MSI+ would have mutations in one of the known DNA mismatch-repair genes. However, MSH2 or MLH1 mutations have been found in less than 10% of UECs with MI+ (Katabuchi et al., 1995; Lim et al., 1996; Kobayashi et al., 1996; Kowalski et al., 1997) . At present, the mechanism by which most sporadic UECs acquire the MSI+ phenotype is not understood. However, a recent study has described transcriptional silencing of the MLH1 gene in association with promoter methylation in a subset of mismatch-repair-defective colon cancer cell lines, one UEC cell line, and in a subset of colon tumors (Kane et al., 1997) . Methylation of normally unmethylated CpG islands in the promoter regions of tumor suppressor genes, including p16/CDKN2A and VHL, correlates with loss of transcription, and suggests an alternative mechanism for tumor suppressor gene inactivation (Herman et al., 1994 Merlo et al., 1995) .
All of the above ®ndings led us to investigate the promoter methylation status of the MLH1 and MSH2 genes in a series of sporadic UECs previously characterized for MSI and DNA MMR gene mutational status. Our results suggest that the presence of the MSI+ phenotype is associated with hypermethylation of the promoter of MLH1 in almost all UECs.
Results
Structurally, MLH1 and MSH2 are candidates for hypermethylation-associated inactivation, because a 5'-CpG island is located around the transcription start site of each gene. We investigated 29 UECs, without previous knowledge of the MSI phenotype and MMR gene mutational status, for promoter hypermethylation of MLH1 and MSH2 genes using Methylation-Speci®c PCR (MSP) (Herman et al., 1996) . We have previously shown that methylation of the promoter region of MLH1 using MSP correlates with the loss of MLH1 expression in primary sporadic colorectal cancer (Herman et al., 1998) , as has been shown using another PCR based approach (Kane et al., 1997) .
Reversal of this methylation, in colorectal and endometrial cancer cell lines, results in restored expression of MLH1 and correction of the MMR defect in these cell lines (Herman et al., 1998) . We found that 13 (45%) of 29 UECs had promoter hypermethylation of the MLH1 gene (Table 1, Figure  1a) . However, none of these tumors had hypermethylation at the 5' CpG island of the MSH2 gene ( Figure  1b) . Moreover, when the EC samples were decoded for their MSI phenotype, MLH1 was hypermethylated in 12 (92%) of 13 MSI+ tumors, and in only one (6%) of 16 MSI7 tumors (Table 1 ) (Fischer's exact test P50.0001). Only one sample known to have the MSI phenotype did not show aberrant hypermethylation of MLH1, but this case had a MSH2 truncating mutation (Table 1) . Excluding the two MSI+ endometrial carcinomas harboring genomic mutations at MSH2, 11 (100%) of 11 MSI+ endometrial tumors had promoter hypermethylation of MLH1 (Table 1) .
To examine if hypermethylation of MLH1 was restricted to MSI+ endometrial carcinomas, we further studied the MLH1 methylation status in 15 gliomas and 10 breast and 20 lung carcinomas, tumor types which do not frequently exhibit the MSI+ phenotype. None of these primary tumors had MLH1 promoter hypermethylation (Figure 1c) .
To test if UECs with the MSI phenotype had an enhanced predisposition for methylation of endogenous sequences in general, as described in MSI+ colon cancers (Ahuja et al., 1997) , we further studied the distribution of p16/CDKN2A promoter methylation in the MSI+ and MSI7 endometrial carcinomas as previously described (Herman et al., 1996) . We found that six (20%) of 29 UECs had promoter hypermethylation of the p16/CDKN2A gene (Figure 2 ). p16/ CDKN2A promoter hypermethylation was found in two (15%) of 13 cases with the MSI phenotype, and four (25%) of 16 MSI7 sporadic UECs. These rates are not statistically dierent (P40.05). Thus, the presence of the MSI phenotype did not correlate with methylation of the p16/CDKN2A gene in these endometrial tumors.
Discussion
Endometrial carcinoma is the most common noncolorectal tumor in female patients with the HNPCC syndrome. Tumors from patients with HNPCC show deletions or additions of one or more tandemly repeated short sequences called microsatellites. Microsatellite instability has also been observed in a subset of sporadic colon and endometrial carcinomas. HNPCC is an inherited disorder attributed to the presence of germ line mutations in one of the genes known to participate in mismatch repair, MSH2, MLH1, hMPS1, hPMS2 and hMSH6/GTBP (Fishel et al., 1993; Leach et al., 1993; Papadopoulos et al., 1994; Bronner et al., 1994; Nicolaides et al., 1994 Nicolaides et al., , 1995 . Such mutations may also account for the MSI phenotype in sporadic tumors, but only a small percentage of sporadic UECs contain mutations in these MMR genes. In fact, only three somatic mutations in MSH2 and one mutation in MLH1 of 61 MSI+ sporadic endometrial carcinomas, have been identi®ed so far (Katabuchi et al., 1995; Lim et al., 1996; Kobayashi et al., 1996; Kowalski et al., 1997) . Thus, the defect responsible for the MSI+ phenotype in most sporadic cases of EC has not been identi®ed.
Our results indicate that MLH1 promoter hypermethylation is a very common feature of endometrial carcinomas with microsatellite instability. Aberrant hypermethylation of 5' CpG islands within proximal promoter regions associated with loss of transcript expression has been implicated as a mechanism by which tumor suppressor genes can be inactivated. Examples of this mechanism have been demonstrated for VHL, E-Cadherin, p15 and p16/CDKN2A (Herman et al., 1994 Merlo et al., 1995) . Recently, lack of MLH1 expression was shown to correlate with cytosine methylation of the MLH1 promoter in a small series of colorectal tumors with the MSI phenotype (Kane et al., 1997) . Lack of MLH1 protein expression is also a common ®nding in immunohistochemistry studies of colon carcinomas with the MSI phenotype Kane et al., 1997) . In fact, the majority of sporadic colorectal cancers with the MSI phenotype have hypermethylation associated inactivation of MLH1 (Herman et al., 1998) . Truncating mutations in MLH1, which may lead to lack of detectable protein, are extremely rare in MSI+ sporadic UECs (Katabuchi et al., 1995; Lim et al., 1996; Kobayashi et al., 1996; Kowalski et al., 1997) . These data support our current ®nding that MLH1 promoter hypermethylation may lead to loss of MLH1 expression and consequently to the appearance of the MSI phenotype in these tumors.
In addition, our data showing the absence of promoter hypermethylation of the MSH2 gene, the other most relevant MMR gene, correlates with previous studies demonstrating that lack of MSH2 expression is not a common event in MSI+ sporadic endometrial tumors, except in those few that carry MSH2 truncating mutations (Katabuchi et al., 1995; Figure 2 Methylation-speci®c PCR of p16/CDKN2A in endometrial carcinomas. PBR322/Msp digest are shown at left as molecular weight markers. Primers sets for ampli®cation are designated as unmethylated (U) or methylated (M). Corresponding lanes are: primary endometrial carcinomas (1 ± 6), SW48 DNA as positive control for methylation, normal lymphocytes as negative control for methylation and water control for PCR reaction Kobayashi et al., 1996) . Interestingly, in our present series, the only sample with MSI phenotype that did not show MLH1 aberrant hypermethylation has a MSH2 truncating mutation.
To our knowledge, our study is the ®rst to show hypermethylation-associated inactivation of p16/ CDKN2A in endometrial carcinoma. Our ®nding that the frequency of p16/CDKN2A hypermethylation does not dier in MSI+ and MSI7 sporadic UECs, suggest that the hypermethylation of p16/CDKN2A may be an independent event not associated with the MSI. Thus, for UECs, genes other than p16/CDKN2A could be the target of the observed increased frequency of hypermethylated genes in MSI+ colon carcinomas (Ahuja et al., 1997) .
In an attempt to determine if the silencing of the MLH1 by promoter hypermethylation is restricted only to MSI+ sporadic endometrial neoplasia, we studied a set of other tumor types, including breast and lung carcinomas and gliomas, which infrequently have the classic MSI+ phenotype. Our evidence that MLH1 is not aberrantly methylated in these tumors suggests that this mechanism is not the cause of the less severe microsatellite alterations occasionally observed in these tumors as compared to the MSI phenotype observed in colon and endometrial carcinomas (Thibodeau et al., 1993; Ionov et al., 1993; Risinger et al., 1993; Burks et al., 1994; Duggan et al., 1994; Kobayashi et al., 1995 Kobayashi et al., , 1996 Cadu et al., 1996; Katabuchi et al., 1995; Lim et al., 1996; Kowalski et al., 1997) . Thus, hypermethylation of MLH1 in sporadic cancers appears to be limited to the tumor types, colon and endometrial, which are prevalent in inherited defects in MMR genes, i.e. HNPCC.
In summary, our current studies suggest that the MSI phenotype in UEC involves hypermethylation of MLH1. This situation appears similar to the MSI phenotype in many sporadic colon cancers (Kane et al., 1997; Herman et al., 1998) , the other tumor type frequently involved with the classic form of mismatch repair defects. It will be interesting to determine: (1) if other MMR genes, like MLH1, can also be epigenetically silenced; (2) the role of MLH1 hypermethylation associated inactivation in larger series of tumors displaying the MSI phenotype; and (3) the eect of MLH1 inactivation on the generation of frameshift somatic mutations in key genes, such as TGFbRII, BAX, hMSH3, hMSH6, and PTEN/ MMAC1. Of these, PTEN/MMAC1 has been recently found to be more frequently mutated in MSI+ sporadic endometrial carcinomas (Tashiro et al., 1997; Kong et al., 1997; Risinger et al., 1997) .
Materials and methods

Tissue specimens and DNA isolation
Tumor samples from 29 patients with endometrial carcinoma were obtained from the Department of Pathology of The Johns Hopkins Hospital. All samples had been previously characterized for MSI and a subset of those with MSI had been assayed for mutations in MLH1, MSH2, hPMS1 and hPMS2 by an IVSP (in vitro synthesized protein) assay (Katabuchi et al., 1995) . The MLH1 and MSH2 promoter methylation study was determined in a blinded fashion with reference to the MSI and DNA MMR mutational status.
Methylation-speci®c PCR (MSP)
DNA methylation patterns in the CpG islands of MLH1 and MSH2 genes were determined by Methylation-Speci®c PCR (Herman et al., 1996) . MSP distinguishes unmethylated from methylated alleles in a given gene based on sequence changes produced following bisul®te treatment of DNA, which converts unmethylated, but not methylated, cytosines to uracil, and subsequent PCR using primers designed for either methylated or unmethylated DNA. One mg of DNA was denatured by treatment with NaOH, and modi®ed by sodium bisul®te. DNA samples were then puri®ed using Wizard DNA puri®cation resin (Promega), again treated with NaOH, precipitated with ethanol, and resuspended in water. Negative controls with no DNA added were included in each PCR reaction. Ten ml of each PCR reaction was directly loaded onto non-denaturing 6% polyacrylamide gels, stained with ethidium bromide, and visualized under UV illumination.
Primer sequences of MLH1 for the unmethylated reaction were 5'-TTT TGA TGT AGA TGT TTT ATT AGG GTT GT-3' (upper primer) and 5'-ACC ACC TCA TCA TAA CTA CCC ACA-3' (lower primer) and for the methylated reaction 5'-ACG TAG ACG TTT TAT TAG GGT CGC-3' (upper primer) and 5'-CCT CAT CGT AAC TAC CCG CG-3' (lower primer). Primer sequences of MSH2 for the unmethylated reaction were 5'-GGT TGT TGT GGT TGG ATG TTG TTT-3' (upper primer) and 5'-CAA CTA CAA CAT CTC CTT CAA CTA CAC CA-3' (lower primer) and for the methylated reaction 5'-TCG TGG TCG GAC GTC GTT C-3' (upper primer) and CAA CGT CTC CTT CGA CTA CAC CG-3' (lower primer). SW48 DNA, which has previously been characterized as methylated at the MLH1 locus (Kane et al., 1997) , was used as a positive control for methylated alleles of MLH1. Since there are no previous reports for cell lines with hypermethylation or loss of expression of MSH2, placental DNA treated in vitro with SssI methyltransferase was used as a positive control for methylated alleles of MSH2. DNA from normal lymphocytes was used as negative control for methylated MLH1 or MSH2 genes. DNA methylation patterns in the 5'-CpG island of p16/CDKN2A were determined as previously described (Herman et al., 1996) .
